Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer

Axsome hopes to end 2019 on a high with its depression drug AXS-05 while Eli Lilly’s pegilodecakin is unlikely to redeem itself in lung cancer.